162 related articles for article (PubMed ID: 19838945)
1. Soy consumption and histopathologic markers in breast tissue using tissue microarrays.
Maskarinec G; Erber E; Verheus M; Hernandez BY; Killeen J; Cashin S; Cline JM
Nutr Cancer; 2009; 61(5):708-16. PubMed ID: 19838945
[TBL] [Abstract][Full Text] [Related]
2. Mammographic density and epithelial histopathologic markers.
Verheus M; Maskarinec G; Erber E; Steude JS; Killeen J; Hernandez BY; Cline JM
BMC Cancer; 2009 Jun; 9():182. PubMed ID: 19523235
[TBL] [Abstract][Full Text] [Related]
3. Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.
Al Tamimi DM; Shawarby MA; Ahmed A; Hassan AK; AlOdaini AA
BMC Cancer; 2010 May; 10():223. PubMed ID: 20492711
[TBL] [Abstract][Full Text] [Related]
4. The association of soy food consumption with the risk of subtype of breast cancers defined by hormone receptor and HER2 status.
Baglia ML; Zheng W; Li H; Yang G; Gao J; Gao YT; Shu XO
Int J Cancer; 2016 Aug; 139(4):742-8. PubMed ID: 27038352
[TBL] [Abstract][Full Text] [Related]
5. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
[TBL] [Abstract][Full Text] [Related]
6. Membrane progesterone receptor alpha as a potential prognostic biomarker for breast cancer survival: a retrospective study.
Xie M; Zhu X; Liu Z; Shrubsole M; Varma V; Mayer IA; Dai Q; Chen Q; You S
PLoS One; 2012; 7(4):e35198. PubMed ID: 22496908
[TBL] [Abstract][Full Text] [Related]
7. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
[TBL] [Abstract][Full Text] [Related]
8. Differential influence of dietary soy intake on the risk of breast cancer recurrence related to HER2 status.
Woo HD; Park KS; Ro J; Kim J
Nutr Cancer; 2012; 64(2):198-205. PubMed ID: 22211813
[TBL] [Abstract][Full Text] [Related]
9. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?
Tovey S; Dunne B; Witton CJ; Forsyth A; Cooke TG; Bartlett JM
Clin Cancer Res; 2005 Jul; 11(13):4835-42. PubMed ID: 16000581
[TBL] [Abstract][Full Text] [Related]
10. Parity and expression of epithelial histopathologic markers in breast tissue.
Morimoto Y; Killeen J; Hernandez BY; Mark Cline J; Maskarinec G
Eur J Cancer Prev; 2013 Sep; 22(5):404-8. PubMed ID: 23222412
[TBL] [Abstract][Full Text] [Related]
11. Dietary soy modulation of biochemical parameters in DMBA-induced mammary tumors.
Gallo D; Ferrandina G; Giacomelli S; Fruscella E; Zannoni G; Morazzoni P; Riva A; Bombardelli E; Mancuso S; Scambia G
Cancer Lett; 2002 Dec; 186(1):43-8. PubMed ID: 12183074
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer subtypes and the risk of local and regional relapse.
Voduc KD; Cheang MC; Tyldesley S; Gelmon K; Nielsen TO; Kennecke H
J Clin Oncol; 2010 Apr; 28(10):1684-91. PubMed ID: 20194857
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: the role of Rad51.
Sosińska-Mielcarek K; Duchnowska R; Winczura P; Badzio A; Majewska H; Lakomy J; Pęksa R; Pieczyńska B; Radecka B; Dębska S; Biernat W; Jassem J
Breast; 2013 Dec; 22(6):1178-83. PubMed ID: 24060578
[TBL] [Abstract][Full Text] [Related]
14. Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer.
Gaedcke J; Traub F; Milde S; Wilkens L; Stan A; Ostertag H; Christgen M; von Wasielewski R; Kreipe HH
Mod Pathol; 2007 Aug; 20(8):864-70. PubMed ID: 17541441
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer in young women and prognosis: How important are proliferation markers?
Fredholm H; Magnusson K; Lindström LS; Tobin NP; Lindman H; Bergh J; Holmberg L; Pontén F; Frisell J; Fredriksson I
Eur J Cancer; 2017 Oct; 84():278-289. PubMed ID: 28844016
[TBL] [Abstract][Full Text] [Related]
16. Soy product and isoflavone intake and breast cancer risk defined by hormone receptor status.
Zhang C; Ho SC; Lin F; Cheng S; Fu J; Chen Y
Cancer Sci; 2010 Feb; 101(2):501-7. PubMed ID: 19860847
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
Allott EH; Geradts J; Sun X; Cohen SM; Zirpoli GR; Khoury T; Bshara W; Chen M; Sherman ME; Palmer JR; Ambrosone CB; Olshan AF; Troester MA
Breast Cancer Res; 2016 Jun; 18(1):68. PubMed ID: 27349894
[TBL] [Abstract][Full Text] [Related]
18. Association of breast cancer subtypes and body mass index.
Petekkaya I; Sahin U; Gezgen G; Solak M; Yuce D; Dizdar O; Arslan C; Ayyildiz V; Altundag K
Tumori; 2013; 99(2):129-33. PubMed ID: 23748802
[TBL] [Abstract][Full Text] [Related]
19. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
Göhring UJ; Scharl A; Ahr A
Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
